Iindaba

I-NEW DELHI, nge-22 kaJuni (Xinhua) — I-Covaxin yomenzi weyeza eIndiya i-Bharat Biotech ibonakalise ukusebenza kakuhle kwe-77.8% kwizilingo zesigaba sesi-III, njengoko kuxeliwe ngamajelo eendaba amaninzi asekuhlaleni ngoLwesibini.

“I-Covaxin yeBharat Biotech isebenza kakuhle ngama-77.8 ekhulwini ekukhuseleni i-COVID-19, ngokwedatha evela kuvavanyo lwesigaba sesi-3 olwenziwe kubathathi-nxaxheba abangama-25,800 kulo lonke elaseIndiya,” itsho ingxelo.

Izinga lokusebenza kakuhle liphume ngoLwesibini emva kokuba ikomiti yeengcali zesifundo (i-SEC) ye-Drug Controller General of India (DCGI) idibene yaza yaxoxa ngeziphumo.

Le nkampani yamayeza ingenise idatha yovavanyo lwesigaba sesiThathu sogonyo kwi-DCGI ngempelaveki.

Iingxelo zithi inkampani kulindeleke ukuba ibambe intlanganiso "yangaphambi kokungeniswa" kunye neegunya zeWorld Health Organisation ngoLwesithathu, ukuze kuxoxwe ngezikhokelo zokungeniswa kokugqibela kwedatha namaxwebhu afunekayo.

I-India yaqala ukugonyelwa i-COVID-19 ngoJan 16 ngokunika amayeza okugonya amabini enziwe eIndiya, iCovishield kunye neCovaxin.

I-Serum Institute of India (SII) yenza iCovishield yase-AstraZeneca-Oxford University, ngelixa iBharat Biotech isebenzisana ne-Indian Council of Medical Research (ICMR) ekwenzeni iCovaxin.

Ugonyo lweSputnik V olwenziwe eRashiya nalo luqalisiwe kweli lizwe.